Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-63709178 |
Synonyms | |
Therapy Description |
JNJ-63709178 is a bispecific antibody that binds to IL3RA (CD123) and CD3, which activates cytotoxic T-lymphocyte response against IL3RA-expressing tumor cells, potentially inducing cytotoxic killing of tumor cells expressing IL3RA (Blood (2016) 128 (22): 2824). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-63709178 | JNJ 63709178|Anti-CD123/CD3 Bispecific Antibody JNJ63709178 | CD3 Antibody 99 | JNJ-63709178 is a bispecific antibody that binds to IL3RA (CD123) and CD3, which activates cytotoxic T-lymphocyte response against IL3RA-expressing tumor cells, potentially inducing cytotoxic killing of tumor cells expressing IL3RA (Blood (2016) 128 (22): 2824). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02715011 | Phase I | JNJ-63709178 | Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Completed | USA | ESP | 0 |